Autophagy

Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021

Retrieved on: 
Wednesday, September 15, 2021
Pathology, Lupus nephritis, Mouse, Immune system, Metabolism, Diabetes, Patient, ACR, Blood, Rheumatoid arthritis, Psoriasis, Pneumonia, Phagocyte, Atopic dermatitis, TLR7, Diabetic nephropathy, NASH, Autophagy, Therapy, NASDAQ, COVID-19, Asthma, GLOBE, CpG, Heart, Immunity, Tissue, Multiple sclerosis, Joint, Fatty liver disease, Skin, Report, Brain, American College of Rheumatology, SEC, Ulcerative colitis, American College, PLXDC2, SLE, COPD, Spleen, Inflammation, Company, Risk, Chronic obstructive pulmonary disease, Disease, Degenerative disease, Infection, LANCL2, NLRX1, Sepsis, Joint Medical Service (Germany), Eosinophilic esophagitis, Pharmaceutical industry

BLACKSBURG, Va., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that it will present preclinical data of LABP-104, an oral, small-molecule LANCL2 agonist, in Systemic Lupus Erythematosus (SLE or Lupus) as an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2021. The meeting will be held virtually from November 3-10, 2021.

Key Points: 
  • platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that it will present preclinical data of LABP-104, an oral, small-molecule LANCL2 agonist, in Systemic Lupus Erythematosus (SLE or Lupus) as an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2021.
  • Landos expects to enter Phase 1 clinical testing of LABP-104 as an oral therapeutic candidate for lupus during the fourth quarter of 2021, further expanding the companys deep inflammation and immunology pipeline.
  • Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism.
  • In addition, the forward-looking statements included in this press release represent the Companys views only as of the date hereof.

Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021

Retrieved on: 
Tuesday, September 14, 2021
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Autophagosome, Medication, IMO, Tissue, Genetic disorder, Cardiac muscle, Patient, Immunohistochemistry, Vacuole, Marketing, LVV, Private Securities Litigation Reform Act, Autophagy, Lists of diseases, Glycogen, Danon disease, Fanconi anemia, Safety, BNP, NASDAQ, Osteopetrosis, COVID-19, Heart Failure Society of America, Bone marrow failure, Heart failure, Lifting, Male, FA, PKD, Risk, AAV, SEC, Pyruvate kinase deficiency, Prevalence, Pharmaceutical industry, Vaccine, RP-A501, Danon Disease, Rocket Pharmaceuticals, Inc., RP-A501, DANON DISEASE, ROCKET PHARMACEUTICALS, INC.

Steroid-induced myopathy was observed in two of the three patients >2 weeks after dosing, which also resolved.

Key Points: 
  • Steroid-induced myopathy was observed in two of the three patients >2 weeks after dosing, which also resolved.
  • In these two patients, a substantial improvement of a key marker of heart failure, B-type natriuretic peptide (BNP), was also observed.
  • RP-A501 is an investigational gene therapy product being developed for Danon Disease and the first potential gene therapy for monogenic heart failure.
  • Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition.

CurePSP funds four new grants to advance treatment of prime of life neurodegeneration

Retrieved on: 
Friday, September 10, 2021

NEW YORK, Sept. 10, 2021 /PRNewswire/ -- CurePSP has awarded Venture Grants totaling $320,000 to scientists at Harvard Medical School, Columbia University, UT Southwestern Medical Center, and UCLA.

Key Points: 
  • NEW YORK, Sept. 10, 2021 /PRNewswire/ -- CurePSP has awarded Venture Grants totaling $320,000 to scientists at Harvard Medical School, Columbia University, UT Southwestern Medical Center, and UCLA.
  • Symptoms include loss of motor control, behavioral disinhibition, cognitive impairment, and difficulties in swallowing and speech.
  • They are termed "prime of life" neurodegeneration because, unlike Alzheimer's disease, they frequently strike in middle age.
  • Currently, there is no effective treatment or cure for these diseases, which affect more than 150,000 people in the U.S. alone.

Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021

Retrieved on: 
Friday, September 10, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that previously disclosed data from the ongoing Phase 1 trial of RP-A501 in Danon Disease will be presented in a late-breaking oral presentation at the upcoming Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that previously disclosed data from the ongoing Phase 1 trial of RP-A501 in Danon Disease will be presented in a late-breaking oral presentation at the upcoming Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021.
  • The meeting will take place September 10-13, 2021 at the Gaylord Rockies Hotel and Conference Center in Aurora, Colorado.
  • Details for Rockets oral presentation are as follows:
    RP-A501 is an investigational gene therapy product being developed for Danon Disease and the first potential gene therapy for monogenic heart failure.
  • Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition.

Adaptive Phage Therapeutics Highlights the Publication of a Case Study of Investigational Phage Therapy for an Antibiotic-Resistant Bacterial Infection in a Child

Retrieved on: 
Thursday, September 9, 2021
Health, Other Health, Clinical Trials, Radiology, Pharmaceutical, Biotechnology

Surgical debridement and hardware removal, as well as three months of intravenously administrated antibiotics failed to stop the pernicious infection.

Key Points: 
  • Surgical debridement and hardware removal, as well as three months of intravenously administrated antibiotics failed to stop the pernicious infection.
  • The investigational phage therapy was prepared by APT and utilized in an effort to prevent the amputation of the patients infected lower leg.
  • The authors state a significant therapeutic effect was observed within two weeks of starting the adjunctive phage therapy.
  • In-vitro activity of multiple phage strain candidates were assessed by means of APTs PhageBank Susceptibility Test (PST) to determine the clinically relevant selection.

PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation

Retrieved on: 
Thursday, September 9, 2021

Autophagy is the natural cellular degradation mechanism that removes unnecessary or dysfunctional components through a lysosome-dependent mechanism.

Key Points: 
  • Autophagy is the natural cellular degradation mechanism that removes unnecessary or dysfunctional components through a lysosome-dependent mechanism.
  • "Insilico is pleased to partner with PAQ Therapeutics to leverage our AI-driven drug discovery platforms in advancing drug R&D of ATTECs to address unmet medical needs."
  • Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and age-related diseases.
  • PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body's most versatile mechanism for natural cellular degradation.

PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation

Retrieved on: 
Thursday, September 9, 2021

Autophagy is the natural cellular degradation mechanism that removes unnecessary or dysfunctional components through a lysosome-dependent mechanism.

Key Points: 
  • Autophagy is the natural cellular degradation mechanism that removes unnecessary or dysfunctional components through a lysosome-dependent mechanism.
  • "Insilico is pleased to partner with PAQ Therapeutics to leverage our AI-driven drug discovery platforms in advancing drug R&D of ATTECs to address unmet medical needs."
  • Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and age-related diseases.
  • PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body's most versatile mechanism for natural cellular degradation.

Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine

Retrieved on: 
Thursday, August 26, 2021
Company, Atopic dermatitis, MS, CNS, Neurology, Therapy, PLXDC2, Disease, Microglia, Rheumatoid arthritis, GLOBE, SEC, Autophagy, Diabetes, Ulcerative colitis, School, Research, Metabolism, Central nervous system, JHU, Alzheimer's disease, National, Neuron, Inflammation, Psoriasis, Medical school, Degenerative disease, NASDAQ, NLRX1, IND, Oxidative phosphorylation, Patient, Immunity, CEO, Lupus nephritis, NIH, Johns Hopkins University, Reactive oxygen species, Brain, COVID-19, Multiple sclerosis, Eosinophilic esophagitis, LANCL2, Pharmaceutical industry, Vaccine

platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that it has entered into a research collaboration with Peter Calabresi, M.D., Director of the Multiple Sclerosis Center and Professor of Neurology at Johns Hopkins University (JHU) School of Medicine.

Key Points: 
  • platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that it has entered into a research collaboration with Peter Calabresi, M.D., Director of the Multiple Sclerosis Center and Professor of Neurology at Johns Hopkins University (JHU) School of Medicine.
  • This research funded by the National Institutes of Health (NIH) will focus on further validating the NLRX1 immunometabolic pathway in Multiple Sclerosis (MS).
  • In contrast, Landos candidate LABP-66 is designed to target the NLRX1 pathway in the CNS and in turn, promote beneficial effects in CD4+ T cells, microglia and neurons.
  • Moreover, Landos pioneering research on the importance of the NLRX1 pathway in immunometabolic control of CD4+ T cells and other autoimmune diseases is complementary to the research Dr. Calabresi is conducting at JHU.

Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501

Retrieved on: 
Monday, August 16, 2021
Other Health, Research, General Health, Pharmaceutical, Genetics, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Other Science, Health, Tissue, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Bone marrow failure, Danon disease, Adult, Male, Genetic disorder, FA, Company, Risk, Food, Private Securities Litigation Reform Act, Lists of diseases, Death, COVID-19, Program, LVV, SEC, Pyruvate kinase deficiency, Autophagy, FDA, Safety management system, Gene expression, PKD, Fanconi anemia, Patient, Osteopetrosis, Lifting, Marketing, IMO, Medication, Heart failure, Glycogen, Safety, AAV, Cardiac muscle, Autophagosome, Prevalence, Pharmaceutical industry, Vaccine, RP-A501, Danon Disease, Rocket Pharmaceuticals, Inc., RP-A501, DANON DISEASE, ROCKET PHARMACEUTICALS, INC.

We are grateful for the collaboration between the FDA and our team in reaching agreement on protocol updates allowing us to resume patient enrollment in our Danon Disease trial.

Key Points: 
  • We are grateful for the collaboration between the FDA and our team in reaching agreement on protocol updates allowing us to resume patient enrollment in our Danon Disease trial.
  • We look forward to progressing this critical work on behalf of all Danon patients, said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma.
  • Rockets Danon Disease program was placed on clinical hold by the FDA in May of 2021 to modify the study protocol and other supporting documents with revised guidelines for patient selection and safety management.
  • Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition.

Longevity Labs Partners With California-Based Upgrade Labs to Provide First Retail-Sales Locations in the United States for Longevity Supplement

Retrieved on: 
Friday, August 13, 2021
Alternative Medicine, General Health, Fitness & Nutrition, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Multimedia, Inflammation, Nail, Spermidine, Heart, Ageing, CEO, E-commerce, Food, University, Disease, Labs, Brain, Hair, Partnership, Semen, Cell, Autophagy, FDA, World, Health, View, Skin, Fasting, Plant, Longevity, Safety, Capsule, Solution, Review, Ribosome, Dietary supplement, Online shopping, Mobile phone operator, Longevity Labs Inc., spermidineLIFE® by Longevity Labs, LONGEVITY LABS INC., SPERMIDINELIFE® BY LONGEVITY LABS

Due to high customer demand, Longevity Labs is partnering with Upgrade Labs, a California-based biohacking facility, to promote and sell spermidineLIFE in its U.S. brick and mortar retail locations.

Key Points: 
  • Due to high customer demand, Longevity Labs is partnering with Upgrade Labs, a California-based biohacking facility, to promote and sell spermidineLIFE in its U.S. brick and mortar retail locations.
  • Upgrade Labs is the worlds first Biohacking facility and brainchild of Dave Asprey, founder of Bulletproof Coffee, CEO of Upgrade Labs, and the father of biohacking.
  • I am happy to now offer spermidineLIFE from Longevity Labs because it helps the body replace damaged cells with younger healthier cells.
  • spermidineLIFE is available at Upgrade Labs locations throughout California and will be offered at a significant discount to Upgrade Labs members.